iCo Therapeutics Announces Third Quarter 2018 Financial Results And Corporate Update
November 29, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or the “Company”) (TSX-V: ICO)
iCo Therapeutics Provides Corporate Update, Including Drug Supply for Next Oral Amphotericin B Efficacy Study
November 15, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or the “Company”) (TSX-V: ICO)
iCo Therapeutics Announces Oral Amphotericin B Clinical Advisory Board
October 23, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or the “Company”) (TSX-V: ICO)
iCo Therapeutics Provides Corporate Update
October 2, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or the “Company”) (TSX-V: ICO)
iCo Therapeutics Announces Additional Positive Pharmacokinetic Results and Presentation at Global Investment Conference
September 6, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or the “Company”) (TSX-V: ICO)
iCo Therapeutics Announces Second Quarter 2018 Financial Results And Corporate Update
August 29, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or the “Company”) (TSX-V: ICO)
iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials – Phase 1 Oral Amphotericin B
July 16, 2018, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V:
iCo Therapeutics Announces Positive Clinical Outcome – Primary Endpoint Met in Phase 1 Oral Amphotericin B Study
June 27, 2018, Vancouver, Canada — iCo Therapeutics Inc. (“iCo” or “the Company”) (TSX-V:
iCo Therapeutics Provides Corporate Update, Announces Completion of Phase 1 Recruitment
June 20, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)
iCo Therapeutics Announces First Quarter 2018 Financial Results And Update On Phase 1 Clinical Trial
May 30, 2018, Vancouver, Canada — iCo Therapeutics (“iCo” or “the Company”) (TSX-V: ICO)